EUVIMEDEUVIMED entdecken
Äquivalenzstudie

A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects

Xiaobei Liu, Xiangrong Dai, Xiaohui Yu, Huan Zhou, Jing Xie

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1479 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Xiaobei Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Anqing Medical College, Anqing, China. Hauptthemen laut MEDLINE: Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Oxadiazoles. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Azilsartan is an angiotensin II receptor blocker used for treating adult hypertension. It significantly improves cardiovascular outcomes in patients with high‐risk hypertension, heart failure, and diabetic nephropathy. A single‐center, randomized, open‐label, single‐dose, dual‐cycle, dual‐crossover clinical trial was conducted to evaluate the bioequivalence of azilsartan under fasting and postprandial conditions in 60 Chinese healthy volunteers. Thirty healthy subjects were enrolled in each test group, with random cross‐administration for fasting and postprandial tests. The concentration of azilsartan in human plasma was evaluated using liquid chromatography‐tandem mass spectrometry after a single oral administration of test and reference preparations, each at a dose of 20 mg (1 tablet). Pharmacokinetic parameters were determined using WinNonlin8.2 software, and bioequivalence was evaluated using SAS 9.4 software. The geometric mean ratios and 90% confidence intervals for maximum concentration, area under the plasma concentration‐time curve from time 0 to the time of last measurable concentration, and area under the plasma concentration‐time curve from time 0 to infinity of the test and reference preparations in the fasting and postprandial test groups were in the range of 80%‐125%. The incidence of adverse events in the fasting and postprandial test groups was 30% (9/30) and 33.3% (10/30), respectively. No serious adverse events or unexpected adverse drug reactions were observed. In conclusion, the test and reference preparations of azilsartan tablets demonstrate bioequivalence and good safety in healthy Chinese subjects under fasting and postprandial conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin II Type 1 Receptor BlockersBenzimidazolesOxadiazolesAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveChinaChromatography, LiquidCross-Over StudiesFastingHealthy VolunteersPostprandial PeriodTandem Mass SpectrometryTherapeutic EquivalencyEast Asian People

Stichwörter der Autor:innen

azilsartanbioequivalenceclinical trialshealthy Chinese subjectspharmacokinetics

Substanzen

Angiotensin II Type 1 Receptor BlockersazilsartanBenzimidazolesOxadiazoles

Autor:innen und Institutionen

  • Anqing Medical College, Anqing, China.
  • Zhaoke Pharmaceutical (Guangzhou) Ltd., Guangzhou, China.
  • National Drug Clinical Trial Institution, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

Zitieren

APA

Liu, X., Dai, X., Yu, X., Zhou, H., & Xie, J. (2024). A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1479

Vancouver

Liu X, Dai X, Yu X, Zhou H, Xie J. A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1479

BibTeX
@article{Liu2024,
  author = {Liu, Xiaobei and Dai, Xiangrong and Yu, Xiaohui and Zhou, Huan and Xie, Jing},
  title = {A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1479}
}
Kostenlos starten →